Profile data is unavailable for this security.
About the company
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABA receptors, targeting both synaptic and extra synaptic GABA receptors. Its product ZULRESSO (brexanolone) CIV injection is for the treatment of PPD in individuals 15 years old and older. It is also developing a portfolio of other novel compounds that target GABA receptors, including SAGE-324, which is a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing. Its second area of focus for development is novel compounds that target the NMDA receptor.
- Revenue in USD (TTM)106.40m
- Net income in USD-337.59m
- Incorporated2010
- Employees487.00
- LocationSAGE Therapeutics Inc215 1st StCAMBRIDGE 02142-1213United StatesUSA
- Phone+1 (617) 299-8380
- Fax+1 (617) 299-8379
- Websitehttps://www.sagerx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lyell Immunopharma Inc | 63.00k | -203.99m | 355.85m | 224.00 | -- | 0.585 | -- | 5,648.46 | -0.8013 | -0.8013 | 0.0003 | 2.07 | 0.00009 | -- | -- | 281.25 | -28.85 | -- | -30.32 | -- | -- | -- | -323,792.10 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
Poseida Therapeutics Inc | 150.86m | -60.76m | 360.32m | 350.00 | -- | 4.14 | -- | 2.39 | -0.635 | -0.635 | 1.56 | 0.8953 | 0.5064 | -- | 12.88 | 457,145.50 | -20.39 | -40.70 | -27.58 | -47.72 | -- | -- | -40.28 | -233.49 | -- | -6.89 | 0.4032 | -- | -50.42 | -- | -92.85 | -- | 19.01 | -- |
Sutro Biopharma Inc | 169.36m | -124.45m | 360.64m | 304.00 | -- | 2.37 | -- | 2.13 | -1.84 | -1.84 | 2.56 | 1.86 | 0.3551 | -- | 19.98 | 560,791.40 | -26.09 | -25.48 | -32.89 | -29.75 | -- | -- | -73.48 | -113.71 | -- | -- | 0.00 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
Tango Therapeutics Inc | 43.38m | -123.40m | 363.07m | 140.00 | -- | 1.58 | -- | 8.37 | -1.15 | -1.15 | 0.4041 | 2.13 | 0.1112 | -- | -- | 309,885.70 | -31.62 | -- | -35.28 | -- | -- | -- | -284.43 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
Compass Pathways PLC (ADR) | 0.00 | -144.32m | 363.31m | 186.00 | -- | 1.88 | -- | -- | -2.19 | -2.19 | 0.00 | 2.82 | 0.00 | -- | -- | 0.00 | -52.83 | -40.85 | -57.18 | -44.48 | -- | -- | -- | -- | -- | -- | 0.1337 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
XOMA Royalty Corp | 21.61m | -35.43m | 364.71m | 13.00 | -- | 4.32 | -- | 16.88 | -3.06 | -3.06 | 1.86 | 7.21 | 0.1244 | -- | 39.72 | 1,662,000.00 | -17.25 | -4.55 | -18.97 | -4.94 | -- | -- | -138.67 | -31.87 | -- | -- | 0.5817 | -- | -21.06 | -2.13 | -105.10 | -- | 23.16 | -- |
enGene Holdings Inc | 0.00 | -123.44m | 364.78m | 33.00 | -- | 1.58 | -- | -- | -4.77 | -4.77 | 0.00 | 5.21 | 0.00 | -- | -- | 0.00 | -78.13 | -- | -84.20 | -- | -- | -- | -- | -- | -- | -3.14 | 0.0906 | -- | -- | -- | -260.87 | -- | -- | -- |
Jasper Therapeutics Inc | 0.00 | -63.53m | 373.55m | 45.00 | -- | 4.43 | -- | -- | -4.75 | -4.75 | 0.00 | 5.58 | 0.00 | -- | -- | 0.00 | -60.56 | -- | -68.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
Design Therapeutics Inc | 0.00 | -47.78m | 374.26m | 54.00 | -- | 1.48 | -- | -- | -0.8465 | -0.8465 | 0.00 | 4.46 | 0.00 | -- | -- | 0.00 | -17.02 | -- | -17.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
Voyager Therapeutics Inc | 143.77m | 9.02m | 382.28m | 162.00 | 45.69 | 1.14 | 27.52 | 2.66 | 0.1534 | 0.1534 | 2.75 | 6.16 | 0.3825 | -- | 43.56 | 887,462.90 | 2.40 | 0.6378 | 2.71 | 0.8203 | -- | -- | 6.28 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
SAGE Therapeutics Inc | 106.40m | -337.59m | 385.39m | 487.00 | -- | 0.6984 | -- | 3.62 | -5.58 | -5.58 | 1.76 | 9.02 | 0.1354 | -- | 5.24 | 218,478.40 | -42.95 | -21.88 | -48.97 | -23.30 | 91.75 | 99.63 | -317.29 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
Northwest Biotherapeutics Inc | 1.65m | -75.55m | 398.19m | 25.00 | -- | -- | -- | 242.06 | -0.0644 | -0.0644 | 0.0014 | -0.047 | 0.0581 | -- | -- | 65,800.00 | -260.06 | -381.58 | -- | -- | -- | -- | -4,479.03 | -6,479.25 | -- | -14.10 | -- | -- | 14.80 | 36.21 | 38.71 | -- | 77.88 | -- |
C4 Therapeutics Inc | 33.67m | -105.50m | 415.06m | 145.00 | -- | 1.71 | -- | 12.33 | -1.70 | -1.70 | 0.5217 | 3.44 | 0.095 | -- | 6.21 | 232,193.10 | -29.76 | -25.91 | -33.20 | -29.45 | -- | -- | -313.35 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
Akebia Therapeutics Inc | 169.88m | -45.99m | 418.47m | 167.00 | -- | -- | -- | 2.46 | -0.2207 | -0.2207 | 0.8338 | -0.2383 | 0.7684 | 1.33 | 6.20 | 1,017,240.00 | -20.80 | -37.42 | -31.00 | -56.00 | 84.79 | 69.13 | -27.07 | -82.25 | 1.21 | -2.52 | -- | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
ProQR Therapeutics NV | 19.93m | -22.95m | 419.38m | 157.00 | -- | 9.53 | -- | 21.04 | -0.2822 | -0.2822 | 0.2449 | 0.4155 | 0.1406 | -- | -- | 126,939.30 | -15.98 | -35.51 | -20.63 | -40.51 | -- | -- | -113.62 | -926.31 | -- | -- | 0.3687 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 5.82m | 9.54% |
The Vanguard Group, Inc.as of 30 Sep 2024 | 5.76m | 9.44% |
RTW Investments LPas of 30 Jun 2024 | 5.48m | 8.98% |
Bellevue Asset Management AGas of 30 Jun 2024 | 4.46m | 7.31% |
BlackRock Fund Advisorsas of 30 Jun 2024 | 3.99m | 6.54% |
SSgA Funds Management, Inc.as of 30 Sep 2024 | 2.93m | 4.79% |
Jacobs Levy Equity Management, Inc.as of 30 Jun 2024 | 1.43m | 2.34% |
Geode Capital Management LLCas of 30 Jun 2024 | 1.24m | 2.03% |
Morgan Stanley & Co. LLCas of 30 Jun 2024 | 1.19m | 1.95% |
Palo Alto Investors LPas of 30 Jun 2024 | 1.01m | 1.66% |